Prednisolone

• HOVON 127 BL / SAKK 37/16: Phase III study comparing 2 treatments (R-CODOX-M/R-IVAC versus DA-EPOCH-R) in patients with Burkitt lymphoma Ended
  2023-503423-25-00 Phase III 2 countries Haemato Oncology Foundation For Adults Netherlands
• Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID Ended
  2023-506949-27-00 Phase II 1 country Odense University Hospital
• CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS Ended
  2024-515164-30-00 Phase IV 1 country Oslo University Hospital HF
• A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended
  2023-506250-20-00 Phase III 8 countries InflaRx GmbH
• BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidne… Ended
  2023-503336-41-00 Phase II 3 countries Eledon Pharmaceuticals Inc.
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended
  2023-505880-35-00 Phase II/III 1 country ROXALL Medizin GmbH
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended
  2023-505567-37-00 Phase II/III 1 country ROXALL Medizin GmbH
• A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended
  2022-500121-33-01 Phase III 12 countries Hansa Biopharma AB
• A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Nega… Ended
  2024-512451-20-00 Phase II/III 1 country Klinikum der Universitaet Muenchen AöR
• Pragmatic, randomized, multicentric, double-blind, controlled clinicial trial on the treatment of acute gout attacks with prednisolone versu… Ended
  2024-514738-18-00 Phase IV 1 country Universitaetsmedizin Greifswald KöR
• Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in postacute inFLAMmatory cardiac involvEment due to COVID… Ended
  2024-516463-84-00 Phase III 2 countries Goethe University Frankfurt
• A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm… Ended
  2024-513658-31-00 Phase II 5 countries AudioCure Pharma GmbH
• A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR) Ended
  2024-517406-29-00 Phase II 2 countries Sparrow Pharmaceuticals Inc.
• An Phase 3 clinical study comparing a vector transferring the gene for Glucose-6-Phosphatase with placebo in adults with Glycogen Storage Di… Ended
  2023-508750-25-00 Phase III 5 countries Ultragenyx Pharmaceutical Inc.
• Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended
  2022-501615-14-00 Phase II 4 countries Merck Sharp & Dohme LLC
• A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti thymocyte … Ended
  2023-507895-36-00 Phase II 3 countries Itb-Med AB
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 Phase III 6 countries AstraZeneca AB
• A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended
  2023-505786-88-00 Phase III 5 countries Astrazeneca AB
• This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use… Ended
  2023-503771-13-00 Phase II 12 countries Spruce Biosciences Inc.
• OPTIMIZE Ended
  2024-516509-22-00 Phase IV 2 countries Universitair Medisch Centrum Groningen
• A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended
  2023-505476-29-00 Phase III 10 countries AbbVie Deutschland GmbH & Co. KG

Showing 97–117 of 117 trials